secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061361
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy Designation to MindMed's MM120 for GAD; Phase 2b shows durable 12-week effect
--------------------------------------------------------------------------------

- FDA breakthrough designation for MM120 (lysergide d-tartrate) to treat generalized anxiety disorder.
- Phase 2b met key secondary endpoint: MM120 100 µg showed 7.7-point HAM-A improvement vs placebo at Week 12 (p<0.003).
- 65% clinical response rate and 48% clinical remission rate sustained to Week 12 from a single dose.
- Plans End-of-Phase 2 meeting with FDA in H1 2024, Phase 3 initiation in H2 2024.
- Terminated ATM prospectus for up to $100M of common shares; no new sales until new prospectus filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312524061361/0001193125-24-061361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312524061361/d682854d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer